These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26337959)

  • 1. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
    Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
    J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
    Zhou J; Chen J; Yu H
    Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
    Guan S; Liu YY; Yan T; Zhou J
    Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
    Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
    Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
    Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
    French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
    J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
    Beljanski V; Lewis CS; Smith CD
    Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
    White MD; Chan L; Antoon JW; Beckman BS
    Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
    Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
    Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
    PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
    Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
    Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
    Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
    Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
    Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
    Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
    Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
    Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
    Poti F; Bot M; Costa S; Bergonzini V; Maines L; Varga G; Freise H; Robenek H; Simoni M; Nofer JR
    Thromb Haemost; 2012 Mar; 107(3):552-61. PubMed ID: 22234485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
    Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
    Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
    McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
    Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.
    Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD
    Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.